Literature DB >> 7916470

Estimating patterns of CD4 lymphocyte decline using data from a prevalent cohort of HIV infected individuals.

E Vittinghoff1, H M Malani, N P Jewell.   

Abstract

In natural history studies of chronic disease, it is of interest to understand the evolution of key variables that measure aspects of disease progression. This is particularly true for immunological variables among persons infected with the human immunodeficiency virus (HIV). The natural time scale for such studies is time since infection. Most data available for analysis, however, arise from prevalent cohorts, where the date of infection is unknown for most or all individuals. As a result, standard curve fitting algorithms are not immediately applicable. Here we propose two methods to circumvent this difficulty. The first uses repeated measurement data to provide information not only on the level of the variable of interest, but also on its rate of change, and is based on the principal curves algorithm of Hastie and Stuetzle. The second uses an external estimate of the expected time since infection. Both methods use locally-weighted linear smoothers, and are applied to data from a prevalent cohort of HIV-infected homosexual men, giving estimates of the average pattern of CD4 lymphocyte decline. These methods apply to natural history studies that use data from prevalent cohorts where the time of disease origin is uncertain, provided availability of certain information from external sources.

Entities:  

Mesh:

Year:  1994        PMID: 7916470     DOI: 10.1002/sim.4780131103

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  2 in total

Review 1.  Generalizations of current status data with applications.

Authors:  N P Jewell; M V Laan
Journal:  Lifetime Data Anal       Date:  1995       Impact factor: 1.588

2.  Early levels of CD4, neopterin, and beta 2-microglobulin indicate future disease progression.

Authors:  M Shi; J M Taylor; J L Fahey; D R Hoover; A Muñoz; L A Kingsley
Journal:  J Clin Immunol       Date:  1997-01       Impact factor: 8.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.